

Biosimilar Policy Subgroup
15 November 2017
Communique

The Biosimilar Policy subgroup of the Access to Medicines Working Group and Generic Medicines Working Group met on 15 November 2017. Attendees included representatives from the Generic and Biosimilar Medicines Association, Medicines Australia, industry and the Department of Health.

This was the first meeting of the Biosimilar Policy subgroup. Members discussed the role of the subgroup and endorsed the scope.

The Biosimilar Policy Subgroup will consider further ways to support a functioning and competitive biosimilars market in Australia. The Subgroup will also monitor and report on current biosimilar policy within the Australian market, in line with the objectives of the National Medicines Policy and the relevant Strategic Agreements.

An update on biosimilar awareness and uptake drivers was also provided.